Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
3,744
Views
6
CrossRef citations to date
0
Altmetric
Brief Report

Replacing the phthalimide core in thalidomide with benzotriazole

Mikhail Krasavina Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, RussiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0200-4772View further author information
ORCID Icon,
Andrey Bubyreva Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, RussiaView further author information
,
Alexander Kazantseva Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, RussiaView further author information
,
Christopher Heimb Department of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, GermanyView further author information
,
Samuel Maiwaldb Department of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, GermanyView further author information
,
Daniil Zhukovskya Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, RussiaView further author information
,
Dmitry Dar’ina Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, RussiaView further author information
,
Marcus D. Hartmannb Department of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, GermanyORCID Iconhttps://orcid.org/0000-0001-6937-5677View further author information
ORCID Icon &
Alexander Bunevc Medicinal Chemistry Center, Togliatti State University, Togliatti, RussiaView further author information
 show all
Pages 527-530 | Received 18 Sep 2021, Accepted 27 Dec 2021, Published online: 28 Feb 2022

References

  • Konstantinidou M, Li J, Zhang B, et al. PROTACs- a game-changing technology. Expert Opin Drug Discov 2019;14:1255–68.
  • Donoghue C, Cubillos-Rojas M, Guitierrez-Prat N, et al. Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation. Eur J Med Chem 2020;201:112451.
  • Zhang Z, Chang X, Zhang C, et al. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). J Enzyme Inhib Med Chem 2020;35:1606–15.
  • (a) Girardini M, Maniaci C, Hughes SJ, et al. Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs. Bioorg Med Chem 2019;27:2466–79. (b) Steinebach C, Sosič I, Lindner S, et al. A MedChem toolbox for cereblon-directed PROTACs. Med Chem Comm 2019;10:1037–41.
  • Xiao D, Wang YJ, Wang HL, et al. Design and synthesis of new lenalidomide analogs via Suzuki cross‐coupling reaction. Arch Pharm 2020;353:1900376.
  • (a) Boichenko I, Bär K, Deiss S, et al. Chemical ligand space of cereblon. ACS Omega 2018;3:11163–71. (b) Heim C, Pliatsika D, Mousavizadeh F, et al. De-novo design of cereblon (CRBN) effectors guided by natural hydrolysis products of thalidomide derivatives. J Med Chem 2019;62:6615–29. (c) Heim C, Maiwald S, Steinebach C, et al. On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. Biochem Biophys Res Commun 2021;534:67–72.
  • Hartmann MD, Boichenko I, Coles M, et al. Structural dynamics of the cereblon ligand binding domain. PLoS One 2015;10:e0128342.
  • Rosso GB. tert-Butoxy bis(dimethyl-amino)methane (Bredereck's reagent). Synlett 2006;809–810.
  • Cui X, Zhang X, Wang W, et al. Regitz diazo transfer reaction for the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles and subsequent regiospecific construction of 1,4-disubstituted 1,2,3-triazoles via C-C bond cleavage. J Org Chem 2021;86:4071–80.
  • Wang K, Chen P, Ji D, et al. Rhodium-catalyzed regioselective N2 -alkylation of benzotriazoles with diazo compounds/enynones via a nonclassical pathway. Angew Chem Int Ed Engl 2018;57:12489–93.
  • Maiwald S, Heim C, Alvarez BH, Hartmann MD. Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay. ACS Med Chem Lett 2021;12:74–81.
  • (a) Fischer ES, Böhm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014;512:49–53. (b) Hartmann MD, Boichenko I, Coles M, et al. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J Struct Biol 2014;188:225–32.
  • Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008;33:219–26.
  • Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002;62:2300–5.
  • Matsuo Y, Drexler HG, Harashima A, et al. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res 2004;28:869–77.
  • Ohtsuki T, Yawata Y, Wada H, et al. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 1989;73:199–204.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.